



April 13<sup>th</sup>, 2026

## Acuitas Therapeutics To Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference

**Vancouver, B.C.** – Acuitas Therapeutics, the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, today announced its participation in the 2026 Bloom Burton & Co. Healthcare Investor Conference. Tom Madden, CEO of Acuitas Therapeutics will deliver a featured presentation and connect with industry leaders throughout the event.

### Bloom Burton & Co. Healthcare Investor Conference

- Presentation Date: April 21<sup>st</sup> at 10:30am
- Location: Toronto, ON, Canada

To schedule a meeting with the Acuitas team during the conference, please visit: [www.acuitastx.com/contact](http://www.acuitastx.com/contact)

### About Acuitas Therapeutics

Acuitas Therapeutics Inc., the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, is a Vancouver-based company collaborating with pharmaceutical and biotech companies, academic researchers, and global health organizations to advance a broad range of medicines for a variety of diseases.

Acuitas' clinically validated LNP technology has had a profound global impact — most notably enabling the Pfizer-BioNTech COVID-19 vaccine, **COMIRNATY®**, which has protected billions of people in more than 180 countries. Its technology also enables **ONPATTRO®** by Alnylam Pharmaceuticals, the first FDA-approved RNAi therapeutic for treating the rare and fatal disease transthyretin amyloidosis. More recently, Acuitas' LNP technology has delivered other groundbreaking firsts: the **first in-human proof of concept** for genome base editing and the **first personalized CRISPR therapy**.

Today, Acuitas is advancing next-generation LNP to support a variety of therapeutic modalities. This includes targeted LNP for extrahepatic and *in vivo* CAR T-cell therapies, epigenetic medicines to modulate gene expression without altering DNA, and multivalent vaccines for infectious diseases — such as malaria, HIV/AIDS, and tuberculosis — as well as oncology vaccines, including personalized cancer vaccines.



For more information, visit [www.acuitastx.com](http://www.acuitastx.com).

-END-

**Media Contact:**

Jakub Cikowski

HDMZ

[acuitas.pr@hdmz.com](mailto:acuitas.pr@hdmz.com)